Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL)
Publication
, Conference
Duvic, M; Olsen, EA; Breneman, D; Pacheco, TR; Parker, S; Vonderheid, EC; Ricker, JL; Rizvi, S; Chen, C; Boileau, K; Cooley, P; Geskin, LJ
Published in: BLOOD
November 16, 2007
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2007
Volume
110
Issue
11
Start / End Page
761A / 761A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Duvic, M., Olsen, E. A., Breneman, D., Pacheco, T. R., Parker, S., Vonderheid, E. C., … Geskin, L. J. (2007). Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). In BLOOD (Vol. 110, pp. 761A-761A). Atlanta, GA: AMER SOC HEMATOLOGY.
Duvic, Madeleine, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sardeta Parker, Eric C. Vonderheid, Justin L. Ricker, et al. “Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL).” In BLOOD, 110:761A-761A. AMER SOC HEMATOLOGY, 2007.
Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). In: BLOOD. AMER SOC HEMATOLOGY; 2007. p. 761A-761A.
Duvic, Madeleine, et al. “Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL).” BLOOD, vol. 110, no. 11, AMER SOC HEMATOLOGY, 2007, pp. 761A-761A.
Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Ricker JL, Rizvi S, Chen C, Boileau K, Cooley P, Geskin LJ. Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). BLOOD. AMER SOC HEMATOLOGY; 2007. p. 761A-761A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2007
Volume
110
Issue
11
Start / End Page
761A / 761A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology